RT Journal Article
SR Electronic
T1 Annual prevalence and treatment estimates of nontuberculous mycobacterial pulmonary disease in Europe: A NTM-NET collaborative study
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP P1067
VO 44
IS Suppl 58
A1 Wagner, Dirk
A1 van Ingen, Jakko
A1 Adjemian, Jennifer
A1 Lange, Christoph
A1 Prevots, D. Rebecca
A1 Griffith, David
A1 Gallagher, Jack
A1 Gupta, Renu
A1 Haworth, Charles
YR 2014
UL http://erj.ersjournals.com/content/44/Suppl_58/P1067.abstract
AB Background: The prevalence of nontuberculous mycobacterial pulmonary disease (NTMPD) has been increasing in Europe; yet, comprehensive analyses and reliable estimates on treatment practices are lacking. We developed methods to assess annual prevalence, and used chart audits to evaluate treatment practices in 5 European countries (EU5): United Kingdom (UK), France, Germany, Italy, and Spain.Methods: NTMPD patients diagnosed annually was estimated by a 2-round Delphi method. A representative sample of physicians extracted treatment information from records of NTMPD patients with a confirmed diagnosis of Mycobacterium avium complex (MAC) or M. abscessus pulmonary disease.Results: Approximately 88% of all physicians contacted and 62% (446) with qualified patients participated. Pulmonologists made up the largest group of study physicians (Italy 17%, UK 38%). In EU5 most NTMPD patients are male (73%) and have a history of smoking (75%); COPD is the most common comorbidity (33%). MAC was the predominant species reported (79%). NTMPD estimated annual prevalence in EU5 ranged from 5.9 (Spain) to 6.5/100,000 (UK). A wide regional heterogeneity within countries was noted, particularly in France (Parisian region [13.6/100,000] vs Southwest region [1.3/100,000]). Logistic regression analysis showed that the decision to treat was most dependent on country (odds ratio = 6.2, Spain vs France) and severity of presenting symptoms (odds ratio = 1.9, severe vs mild).Conclusions: Annual prevalence of NTMPD is uniform on a per capita basis in EU5, but heterogeneous within different regions. The percentage of patients treated varies widely by country and severity.